Pharma marketers increasingly recognize that nurse practitioners and physician assistants (NPs & PAs) are essential to the treatment journey. Yet in many organizations, Advanced Practice Providers (APPs) are still treated as a secondary segment of a physician-focused HCP strategy.

The assumption is that existing HCP campaigns already reach APPs. The same clinical messages, creative assets and media placements are expected to work for both audiences. But reaching APPs incidentally is not the same as engaging them effectively. APPs have distinct clinical responsibilities, patient relationships, information needs and communication preferences. To build strategies that reflect those differences, pharma marketers need more than demographic data or an occasional focus group. They need an ongoing connection to the clinicians they are trying to influence.

That is the purpose of the LiveWorld APP Research Council: a contracted panel of practicing NPs and PAs representing 24 therapeutic specialties, available to help brand teams develop, test and improve APP-focused research, strategy, messaging, creative and media programs.

The APP opportunity is becoming impossible to ignore

APPs are no longer an emerging HCP audience. They are an established and growing part of the healthcare workforce, frequently managing patients, discussing treatment options, writing prescriptions and influencing decisions throughout the care team. The industry’s challenge is not simply recognizing their importance. It is translating that recognition into a dedicated marketing approach.

In many HCP plans, APPs remain folded into a broader physician audience. Campaigns may reach them, but brand teams often lack evidence that their physician-oriented content addresses APP workflows, objections or patient conversations. That distinction matters because APPs do not necessarily evaluate information or interact with pharma in the same ways physicians do.

HealthLink Dimensions’ 2025 NP/PA Communications Report reinforces the need for a more deliberate strategy. According to the report:

• Email remains the preferred industry communication channel for 73% of respondents.
• Most NPs and PAs prefer outreach weekly or twice per month.
• Early afternoon is the most effective time to connect.
• Two-thirds notice professional advertising online.
• Nearly nine in ten are receptive to digital advertising when it is relevant to their clinical work.
• Product approvals, CME opportunities and patient education materials are among the information sources they value most.

These findings show that APPs are reachable and receptive. But they also show that relevance, usefulness, timing and context determine whether outreach earns attention or becomes another interruption.

What APPs want pharma marketers to understand

Responses from members of LiveWorld’s APP community reveal a consistent message: strong clinical data alone does not make a therapy practical to prescribe. APPs must balance clinical guidelines with insurance restrictions, affordability, patient preferences, treatment complexity and limited time. Marketing that does not acknowledge those realities can quickly lose credibility.

Affordability and access are part of the product story

Cost emerged as the most prominent theme in the Council discussion. As NP Kendra G. explained: “Even a great medication isn’t always helpful if it’s too expensive or difficult to obtain.”

Other Council participants described situations in which representatives said a medication was “covered,” only for patients to discover that they still faced hundreds of dollars in out-of-pocket costs. Members also noted that copay cards may provide little or no help to patients covered by Medicaid or other programs that make them ineligible. The implication for marketers is significant: affordability information cannot be treated as a footnote after the clinical story. APPs want an honest picture of what obtaining and staying on a therapy will involve for their patients.

That includes information such as:

• Likely coverage and out-of-pocket costs
• Prior authorization requirements
• Patient eligibility for savings programs
• Access limitations affecting government-insured patients
• Practical steps for resolving coverage problems
• The amount and duration of sample support

When these questions go unanswered, APPs are left to manage the frustration created by the brand promise.

Workflow friction can outweigh clinical enthusiasm

Prior authorization was another recurring concern. Council member Caroline C. described prior authorizations as disruptive to “the clinic, providers, patients and pharmacies.” Other participants discussed the administrative cycle that can follow a prescription: denials, calls from patients, appeals, substitutions and additional conversations with pharmacies and insurers.

For a busy APP, prescribing is not one isolated decision. It can create a chain of downstream work. That is why practical access information may be as important as efficacy data in an APP engagement. A campaign should help clinicians understand not only why a medication may be appropriate, but also how realistically it can move from prescription to patient.

Patient usability matters

APPs also emphasized the difference between a treatment that works in a clinical study and a treatment that works in a patient’s daily life.

Administration instructions, dosing frequency, side effects and required lifestyle adjustments can influence whether patients begin or remain on therapy. As one Council member noted, a medication can be affordable and clinically effective but still fail if the patient cannot follow the treatment plan correctly. Others highlighted side effects affecting quality of life, including appetite, sleep, libido and sedation, as information that should be addressed clearly.

This patient-centered perspective is especially important because APPs often play a major role in education, adherence and shared decision-making. They need information they can translate into real conversations, not simply product claims developed for promotional materials.

Engagement must respect limited time

Council member Candice S. summarized another practical reality: “We are so busy. Please have a speech you can give me in under five minutes.” APPs are asking for concise, clinically relevant communication, not a compressed version of a long sales presentation. Jay W. offered a similarly direct recommendation: “Give me quick, honest, clinically relevant information with real-world access solutions, not a sales pitch.”

This does not mean APPs are unreceptive to pharma communication. The HealthLink Dimensions findings suggest the opposite: NPs and PAs are highly receptive when communication is relevant to their clinical work. It means relevance must be demonstrated quickly.

Why an ongoing Research Council changes the process

Traditional research often asks clinicians to react to nearly finished work. A brand develops its positioning, message architecture and creative concepts, then recruits a group of APPs to validate what has already been decided. At that point, meaningful changes may be difficult, expensive or politically challenging. The LiveWorld model brings APPs into the process earlier and more consistently.

Council members can participate in:

• Research and insight generation: Therapeutic-area-matched APPs help identify unmet needs, prescribing barriers, information behaviors and attitudes before the strategy is developed.
• Audience strategy: Their input informs segmentation, positioning and recommendations for engaging APPs as a distinct audience rather than a secondary physician segment.
• Message and creative co-creation: APPs can react to early concepts, clinical framing, tone and proof points while there is still time to improve them.
• Material review: Council members review existing HCP websites, sales aids, educational materials and campaign assets to identify where physician-first content fails to address APP needs.
• Creative and content testing: Draft materials are pressure-tested with the clinicians they are intended to influence, helping teams uncover confusion, objections or credibility gaps before launch.
• Media strategy validation: Council input complements quantitative channel data by explaining where, when and why APPs pay attention.
• Post-launch optimization: The Council can continue reviewing live campaign experiences and performance findings instead of disappearing after the initial research phase.

The result is not merely “APP-reviewed” marketing. It is marketing built with APPs.

From practitioner insight to measurable performance

The Council becomes even more valuable when its input is connected to campaign execution and measurement. Within LiveWorld’s APP pilot model, Council insights guide a complete research-to-results program encompassing strategy, creative development, media planning, campaign execution and performance analysis. The goal is to replace the assumption that a general HCP campaign “already covers APPs” with measurable evidence of what actually engages them.

Council feedback also becomes a structured input into LiveInsight AI™ Intelligence System, where it can be synthesized with relevant HCP, APP and patient social conversations, clinical literature and other approved intelligence sources. This allows individual comments to become part of a broader, continually developing understanding of the therapeutic area. For brand marketers, that creates a valuable feedback loop:

Listen to APPs. Build with their input. Test before launch. Activate the strategy. Measure the response. Learn and improve.

The new standard: practitioner-informed, not physician-adapted

The question is no longer whether APPs should be included in HCP marketing. The more useful questions are:

• Do we understand their specific barriers and motivations?
• Can we prove our messages are relevant to their clinical reality?
• Are we giving them practical information they can use with patients?
• Have APPs helped shape the campaign, or did we simply show it to them after it was finished?
• Can we measure APP reach and engagement independently from the broader HCP audience?

Brands that cannot answer those questions are not necessarily failing to reach APPs. They may be failing to recognize them.

The LiveWorld APP Research Council gives pharma marketers a direct, ongoing connection to practicing NPs and PAs across therapeutic specialties, turning APP insight from a one-time research exercise into an intelligence engine that informs the entire campaign lifecycle. Because the most reliable way to understand what APPs need is not to keep making assumptions about them. It is to ask them and build the strategy with them.

Ready to put frontline APP insight at the center of your next HCP campaign? Contact LiveWorld to explore an APP Research Council engagement or a Council-informed pilot program.